Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
Bristol-Myers Squibb
AstraZeneca
BeOne Medicines
Synthekine
BeOne Medicines
Boehringer Ingelheim
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Janssen Research & Development, LLC
Novartis
Gilead Sciences
BioNTech SE
Bristol-Myers Squibb
AbbVie
Seagen Inc.
Genmab
Merck Sharp & Dohme LLC
Seagen Inc.
Merck Sharp & Dohme LLC
Astellas Pharma Inc
Boehringer Ingelheim
AstraZeneca
AstraZeneca
Xencor, Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Eli Lilly and Company
Pfizer
Mirati Therapeutics Inc.
Eli Lilly and Company
BioNTech SE
Hoffmann-La Roche
Merck Sharp & Dohme LLC
AstraZeneca
Hoffmann-La Roche
AstraZeneca
Merck Sharp & Dohme LLC
Incyte Corporation
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Arcus Biosciences, Inc.
Akeso
Akeso
Revolution Medicines, Inc.
Verastem, Inc.
AstraZeneca
Qilu Pharmaceutical Co., Ltd.
Hoffmann-La Roche
Akeso
RemeGen Co., Ltd.